RT with Aperio LV1 and Mikroscan D2 for parathyroid frozen section interpretation has a high rate of concordant diagnoses compared with in-house microscopy. Slide interpretation times with these two RT systems are longer than in-house interpretation but less for Aperio LV1 compared with Mikroscan D2. Aim: To compare recipients receiving standard dose cyclosporin (CSA) and mycophenolate, changing to everolimus (EVL) or continuing with CSA between 3 and 4 months post-transplant on left ventricular mass index (LVMI) and arterial stiffness.
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Methods:
We recruited 24 patients in this 18-month randomised, openlabel, controlled trial, evaluated the effect of CSA withdrawal for EVL at 3 months post-transplant on LVMI (primary outcome), arterial stiffness (aortic augmentation index (AIx) and pulse wave velocity (PWV)) and eGFR (secondary outcomes) compared to CSA and mycophenolate of 24 kidney transplant recipients (with the power to detect a 20% difference in LVMI between groups at 18 months post-transplant with 80% power). No patients were lost to follow-up.
Results: Mean donor and recipient age, proportion of live donors and diabetes were similar between treatment groups. Mean (SD) LVMI was similar at 3 months (124 (43) vs 124 (37) g/m) and 18 months (124 (36) vs 125 (37) g/m) in both EVL and CSA groups (ANOVA P = 0.67). There were no significant differences in mean AIx or PWV between treatment groups at 3 and 18 months or within treatment groups between 3 and 18 months after transplantation. There was significant improvement in mean (SD) eGFR between 3 and 18 months amongst patients randomised to the EVL group (53 (14) to 64 (13) ml/min/1.73 m 2 , paired t-test P < 0.01), but not in the CSA group (54 (17) to 53 (18) ml/min/1.73 m 2 , P = 0.89). Proportion experiencing rejection was similar in both groups with no graft loss or death in either group. Background: Numerous neuroinflammatory conditions such as multiple sclerosis show enhanced expression of the purinergic P2X7 receptor (P2X7R) in the neuroinflammatory foci, where increased microglial activation is a co-existing feature. Activated microglia are known to release a number of bio-active substances such as interleukin 1β (IL-1β). Previous studies have linked P2X7R stimulation to the processing and release of IL-1β, but whether P2X7R channel or P2X7R pore is the predominant entity driving that release is unknown. Also the effect of released IL-1β on microglial activation and proliferation is unclear. The aim of this study was to characterise IL-1β release dynamics from microglia.
Conclusion
INTERLEUKIN-1β HAS TROPHIC EFFECTS IN MICROGLIA AND ITS RELEASE IS MEDIATED BY P2X7R PORE
Methods:
Primary hippocampal rat cultures with electron microscopy and immunohistochemistry was used to delineate the sub-cellular localisation of IL-1β. FM1-43 fluorescent dye and confocal microscopy were used to quantify vesicular exocytosis from microglia expressing the pore forming P2X7R versus a non-pore forming point mutant, P2X7RG345Y. Amount of IL-1β in culture was quantified with enzyme-linked immunosorbent assay (ELISA). IL-1β intracellular processing was blocked with inhibition of caspase 1 and its extracellular form was neutralised with an IL-1β neutralising antibody. Microglial activation and proliferation was quantified immunohistochemically and with aid of confocal microscopy.
Results:
Immunohistochemistry revealed P2X7R and IL-1β colocalisation in lysosomes. Vesicular exocytosis was higher in microglia expressing the pore forming P2X7R compared to those expressing the non-pore forming mutant. IL-1β levels were raised in cultures expressing the pore forming P2X7R and this cytokine was found to mediate the trophic effects of P2X7R pore in microglia. Inhibition of IL-1β production and function resulted in a significant decrease in P2X7R-mediated microglial activation and proliferation.
Conclusion:
The results reveal IL-1β as a mediator of microglial activation and proliferation. Blockade of P2X7R pore could serve as a therapeutic target in alleviating the degree of inflammation seen in conditions such as multiple sclerosis.
